M&A / Deals Lilly boosts ADC portfolio with CrossBridge Bio deal BioPharma DiveWorth up to $300 million, the buyout is Lilly s latest of an ADC maker and adds technology for making dual-payload therapies.M&A / DealsOncologyRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) BioPharma Dive Worth up to $300 million, the buyout is Lilly s latest of an ADC maker and adds technology for making dual-payload therapies. M&A / DealsOncologyRead full story Post navigation Previous: Lilly investing billions to prepare for overseas oral GLP-1 launchesNext: With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026 Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026